Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 Oct 28:3:31.
doi: 10.1186/s40169-014-0031-4. eCollection 2014.

Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer

Mounira El Demery  1 , Gaiané Demirdjian-Sarkissian  2 , Simon Thezenas  3 , William Jacot  4 , Yassine Laghzali  3 , Bruno Darbouret  2 , Stéphane Culine  5 , Xavier Rebillard  6 , Pierre-Jean Lamy  7
Affiliations

Serum Matrix Metalloproteinase-7 is an independent prognostic biomarker in advanced bladder cancer

Mounira El Demery et al. Clin Transl Med. .

Abstract

Background: Urine markers have been studied extensively but there is a lack of blood prognostic markers in bladder cancer. MMP-7 is produced by stromal cells and by tumor cells and is overexpressed in a variety of epithelial and mesenchymal tumors. In this study, we assessed with an immunoassay we developed, the prognostic value of serum MMP-7 in a series of patients with advanced bladder cancer.

Methods: Serum samples were collected from 56 patients with advanced bladder cancer who were treated at the Montpellier Cancer Institute between March 2003 and December 2004. MMP-7 was quantified in serum samples by using a homogeneous sandwich fluoroimmunoassay we developed based on the time resolved amplified cryptate emission (TRACE) technology.

Results: The median overall survival of the study population was 2.2 years (95% CI, 1.4 to 3.0) with 1- and 5-year survival rates of 73% (95% CI, 59% to 82%) and 25% (95% CI, 14% to 37%), respectively. High MMP-7 serum levels were associated with poor survival. Using a cut-off value of 11.5 ng/mL, the median overall survival was 3.0 years (95% CI, 1.5 to 5.1) for patients with MMP-7 serum level <11.5 ng/mL and 1.3 years (95% CI, 0.8 to 2.5) for patients with serum level ?11.5 ng/mL. Multivariate analysis identified high MMP-7 serum concentration as an independent prognostic factor for survival in patients with advanced bladder cancer (R?=?2.1, 95% CI, 1.1 to 4.4).

Conclusions: Our results show that the MMP-7 serum concentration is an independent prognostic factor in patients with locally advanced and or metastatic bladder cancer.

Keywords: Biomarker; Bladder cancer; MMP-7; Overall survival; Prognosis; Serum; Tumor markers; Urothelial tumors.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Overall survival probability function according to serum MMP-7 level in bladder cancer.
See this image and copyright information in PMC

References

    1. Grosclaude P, Velten M, Daubisse-Marliac L. Incidence of urogenital Tumors. Binder-Foucard F, Belot A, Delafosse P, et al. Estimation nationale de l¿incidence et de la mortalité par cancer en France entre 1980 et 2012. Tumeurs solides. Saint-Maurice (Fra): Institut de veille sanitaire. 2013.
    1. Babjuk M, Oosterlinck W, Sylvester R, Kaasinen E, Bohle A, Palou-Redorta J. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder. Eur Urol. 2008;54:303–314. doi: 10.1016/j.eururo.2008.04.051. - DOI - PubMed
    1. Sylvester RJ, van der Meijden AP, Oosterlinck W, Witjes JA, Bouffioux C, Denis L, Newling DW, Kurth K. Predicting recurrence and progression in individual patients with stage Ta T1 bladder cancer using EORTC risk tables: a combined analysis of 2596 patients from seven EORTC trials. Eur Urol. 2006;49:466–465. doi: 10.1016/j.eururo.2005.12.031. discussion 475-467. - DOI - PubMed
    1. Shariat SF, Karakiewicz PI, Palapattu GS, Lotan Y, Rogers CG, Amiel GE, Vazina A, Gupta A, Bastian PJ, Sagalowsky AI, Schoenberg MP, Lerner SP. Outcomes of radical cystectomy for transitional cell carcinoma of the bladder: a contemporary series from the Bladder Cancer Research Consortium. J Urol. 2006;176:2414–2422. doi: 10.1016/j.juro.2006.08.004. discussion 2422. - DOI - PubMed
    1. Karakiewicz PI, Shariat SF, Palapattu GS, Gilad AE, Lotan Y, Rogers CG, Vazina A, Gupta A, Bastian PJ, Perrotte P, Sagalowsky AI, Schoenberg MP, Lerner SP. Nomogram for predicting disease recurrence after radical cystectomy for transitional cell carcinoma of the bladder. J Urol. 2006;176:1354–1361. doi: 10.1016/j.juro.2006.06.025. discussion 1361-1352. - DOI - PubMed